$NBY
NovaBay Pharmaceuticals Inc Stock $nby

$nby Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000143774922007543 Filed on March 29, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$2.641M	$8.421M	$1.888M
YoY Change	39.88%	-15.23%	10.8%
Cost Of Revenue	$1.214M	$2.776M	$813.0K
YoY Change	49.32%	-30.08%	37.1%
Gross Profit	$1.427M	$5.645M	$1.075M
YoY Change	32.74%	-5.35%	-3.24%
Gross Profit Margin	54.03%	67.03%	56.94%
Selling, General & Admin	$4.613M	$14.46M	$2.797M
YoY Change	64.93%	19.48%	-16.03%
% of Gross Profit	323.27%	256.21%	260.19%
Research & Development	$8.000K	$44.00K	$40.00K
YoY Change	-80.0%	-84.56%	122.22%
% of Gross Profit	0.56%	0.78%	3.72%
Depreciation & Amortization	$87.00K	$119.0K	$11.00K
YoY Change	690.91%	133.33%	-26.67%
% of Gross Profit	6.1%	2.11%	1.02%
Operating Expenses	$4.621M	$14.51M	$2.833M
YoY Change	63.11%	17.09%	-15.41%
Operating Profit	-$3.194M	-$8.862M	-$1.758M
YoY Change	81.68%	37.91%	-21.45%
Interest Expense	$4.615M	$4.615M	$8.000K
YoY Change	57587.5%	-188.53%	-101.78%
% of Operating Profit
Other Income/Expense, Net	-$1.577M	-$1.577M	$0.00
YoY Change		-360.66%	-100.0%
Pretax Income	-$156.0K	-$5.824M	-$1.750M
YoY Change	-91.09%	-47.22%	-34.77%
Income Tax	$0.00	$0.00	$4.000K
% Of Pretax Income
Net Earnings	-$156.0K	-$5.824M	-$1.754M
YoY Change	-91.11%	-47.24%	-34.7%
Net Earnings / Revenue	-5.91%	-69.16%	-92.9%
Basic Earnings Per Share		-$0.15
Diluted Earnings Per Share	-$3.442K	-$133.4K	-$41.31K
COMMON SHARES
Basic Shares Outstanding	44.94M	43.66M
Diluted Shares Outstanding

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.504M	$7.504M	$11.95M
YoY Change	-37.22%	-37.22%	72.29%
Cash & Equivalents	$7.504M	$7.504M	$11.95M
Short-Term Investments
Other Short-Term Assets	$145.0K	$778.0K	$102.0K
YoY Change	42.16%	35.07%	-35.85%
Inventory	$3.220M	$3.220M	$608.0K
Prepaid Expenses
Receivables	$1.668M	$1.668M	$1.106M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$13.17M	$13.17M	$14.24M
YoY Change	-7.53%	-7.53%	51.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$193.0K	$604.0K	$84.00K
YoY Change	129.76%	16.15%	-23.64%
Goodwill	$4.528M		$0.00
YoY Change
Intangibles	$5.200M		$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$476.0K	$476.0K	$476.0K
YoY Change	0.0%	0.0%	-0.21%
Total Long-Term Assets	$10.81M	$10.81M	$996.0K
YoY Change	985.14%	985.14%	-45.84%
TOTAL ASSETS
Total Short-Term Assets	$13.17M	$13.17M	$14.24M
Total Long-Term Assets	$10.81M	$10.81M	$996.0K
Total Assets	$23.98M	$23.98M	$15.24M
YoY Change	57.36%	57.36%	35.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.045M	$1.045M	$302.0K
YoY Change	246.03%	246.03%	-8.76%
Accrued Expenses	$2.092M	$1.003M	$2.115M
YoY Change	-1.09%	-44.31%	18.95%
Deferred Revenue	$1.272M		$575.0K
YoY Change	121.22%		32.49%
Short-Term Debt	$105.0K	$105.0K	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.442M	$3.442M	$2.833M
YoY Change	21.5%	21.5%	-50.18%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$10.37M	$10.37M	$87.00K
YoY Change	11813.79%	11813.79%
Total Long-Term Liabilities	$10.37M	$10.37M	$87.00K
YoY Change	11813.79%	11813.79%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.442M	$3.442M	$2.833M
Total Long-Term Liabilities	$10.37M	$10.37M	$87.00K
Total Liabilities	$13.81M	$13.81M	$2.920M
YoY Change	372.84%	372.84%	-71.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$141.9M		-$136.1M
YoY Change	4.28%		8.83%
Common Stock	$478.0K		$418.0K
YoY Change	14.35%		49.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.17M	$10.17M	$12.32M
YoY Change
Total Liabilities & Shareholders Equity	$23.98M	$23.98M	$15.24M
YoY Change	57.36%	57.36%	35.81%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$156.0K	-$5.824M	-$1.754M
YoY Change	-91.11%	-47.24%	-34.7%
Depreciation, Depletion And Amortization	$87.00K	$119.0K	$11.00K
YoY Change	690.91%	133.33%	-26.67%
Cash From Operating Activities	-$4.318M	-$9.192M	-$1.445M
YoY Change	198.82%	94.7%	1.12%
INVESTING ACTIVITIES
Capital Expenditures	-$8.000K	$52.00K	-$21.00K
YoY Change	-61.9%	100.0%
Acquisitions		$11.99M
YoY Change
Other Investing Activities	-$11.99M	-$11.99M
YoY Change
Cash From Investing Activities	-$12.00M	-$12.05M	-$21.00K
YoY Change	57047.62%	46226.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$1.776M
YoY Change		-65.98%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	14.80M	$16.79M	5.000K
YoY Change	295800.0%	71.98%	-100.76%
NET CHANGE
Cash From Operating Activities	-4.318M	-$9.192M	-1.445M
Cash From Investing Activities	-12.00M	-$12.05M	-21.00K
Cash From Financing Activities	14.80M	$16.79M	5.000K
Net Change In Cash	-1.524M	-$4.448M	-1.461M
YoY Change	4.31%	-188.69%	-29.86%
FREE CASH FLOW
Cash From Operating Activities	-$4.318M	-$9.192M	-$1.445M
Capital Expenditures	-$8.000K	$52.00K	-$21.00K
Free Cash Flow	-$4.310M	-$9.244M	-$1.424M
YoY Change	202.67%	94.73%	-0.35%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Auditor Firm AuditorFirmId	100
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	641000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	236000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	14000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	14000
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47766000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47766000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41782000
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41782000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2020	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7504000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11952000	USD
CY2021Q4	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	1668000	USD
CY2020Q4	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	1106000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	3220000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	608000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	778000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	576000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	13170000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	14242000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	411000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	436000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	193000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	84000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	4528000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	0	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5200000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	476000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	476000	USD
CY2021Q4	us-gaap	Assets Assets	23978000	USD
CY2020Q4	us-gaap	Assets Assets	15238000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1045000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	302000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2092000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2115000	USD
CY2021Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	105000	USD
CY2020Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	0	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	200000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	416000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3442000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2833000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	246000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	87000	USD
CY2021Q4	nby	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	9558000	USD
CY2020Q4	nby	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	0	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	561000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	USD
CY2021Q4	us-gaap	Liabilities Liabilities	13807000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	2920000	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	680000	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	478000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	418000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	150900000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	147963000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-141887000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-136063000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	10171000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	12318000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23978000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15238000	USD
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8421000	USD
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9934000	USD
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6599000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2776000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3970000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1738000	USD
CY2021	us-gaap	Gross Profit GrossProfit	5645000	USD
CY2020	us-gaap	Gross Profit GrossProfit	5964000	USD
CY2019	us-gaap	Gross Profit GrossProfit	4861000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	285000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	184000	USD
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7223000	USD
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6173000	USD
CY2019	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8767000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7240000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5932000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5310000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	14507000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	12390000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	14261000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-8862000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-6426000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-9400000	USD
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4615000	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	5216000	USD
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-749000	USD
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	3000	USD
CY2019	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	424000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1577000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	605000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1425000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5824000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11034000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9652000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-5824000	USD
CY2019	nby	Stock Based Compensation Expense Related To Non Employee And Director Stock Options StockBasedCompensationExpenseRelatedToNonEmployeeAndDirectorStockOptions	37000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-11039000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-9658000	USD
CY2021	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	735000	USD
CY2020	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
CY2019	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	800000	USD
CY2021	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	0	USD
CY2020	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	0	USD
CY2019	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	29000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6559000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11039000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10487000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43657000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35076000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21641000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	4954000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-9658000	USD
CY2019	nby	Reclassification Of Warrant Liability To Equity ReclassificationOfWarrantLiabilityToEquity	56000	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3502000	USD
CY2019	nby	Stock Issued In Connection With Exercise Of Warrants Value StockIssuedInConnectionWithExerciseOfWarrantsValue	620000	USD
CY2019	nby	Restricted Stock Units Issued Value Related To Employee Separation Agreement RestrictedStockUnitsIssuedValueRelatedToEmployeeSeparationAgreement	220000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	189000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	334000	USD
CY2019	nby	Adjustments To Additional Paid In Capital Stock Option Modification AdjustmentsToAdditionalPaidInCapitalStockOptionModification	105000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	973000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-11039000	USD
CY2020	nby	Reclassification Of Warrant Liability To Equity ReclassificationOfWarrantLiabilityToEquity	197000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5220000	USD
CY2020	nby	Stock Issued In Connection With Exercise Of Warrants Value StockIssuedInConnectionWithExerciseOfWarrantsValue	16206000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	415000	USD
CY2020	nby	Stock Based Compensation Expense Related To Non Employee And Director Stock Options StockBasedCompensationExpenseRelatedToNonEmployeeAndDirectorStockOptions	64000	USD
CY2020	nby	Adjustments To Additional Paid In Capital Stock Option Modification AdjustmentsToAdditionalPaidInCapitalStockOptionModification	53000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	12318000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-5824000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	13000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1776000	USD
CY2021	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	735	USD
CY2021	nby	Adjustments To Additional Paid In Capital Beneficial Conversion Feature Upon Issuance Of Stock AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureUponIssuanceOfStock	735000	USD
CY2021	nby	Adjustments To Additional Paid In Capital Deemed Dividend From Beneficial Conversion Feature Of Stock AdjustmentsToAdditionalPaidInCapitalDeemedDividendFromBeneficialConversionFeatureOfStock	-735000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	693000	USD
CY2021	nby	Stock Based Compensation Expense Related To Non Employee And Director Stock Options StockBasedCompensationExpenseRelatedToNonEmployeeAndDirectorStockOptions	240000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	10171000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-5824000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-11039000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-9658000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	119000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	51000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	65000	USD
CY2021	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	-0	USD
CY2020	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	54000	USD
CY2019	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	-0	USD
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	USD
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	141000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	670000	USD
CY2021	nby	Interest Expense Related To Amortization Of Debt Issuance Related To Related Party Notes Payable InterestExpenseRelatedToAmortizationOfDebtIssuanceRelatedToRelatedPartyNotesPayable	0	USD
CY2020	nby	Interest Expense Related To Amortization Of Debt Issuance Related To Related Party Notes Payable InterestExpenseRelatedToAmortizationOfDebtIssuanceRelatedToRelatedPartyNotesPayable	2000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	317000	USD
CY2020	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	USD
CY2019	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	32000	USD
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-0	USD
CY2020	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-1000	USD
CY2019	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-3000	USD
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	USD
CY2020	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	USD
CY2019	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	125000	USD
CY2021	nby	Share Based Compensation Expense For Stock Option Modification ShareBasedCompensationExpenseForStockOptionModification	0	USD
CY2020	nby	Share Based Compensation Expense For Stock Option Modification ShareBasedCompensationExpenseForStockOptionModification	53000	USD
CY2019	nby	Share Based Compensation Expense For Stock Option Modification ShareBasedCompensationExpenseForStockOptionModification	105000	USD
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4615000	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	5216000	USD
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-749000	USD
CY2021	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-0	USD
CY2020	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	3000	USD
CY2019	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	424000	USD
CY2019	nby	Interest Expense Related To Amortization Of Debt Issuance Related To Related Party Notes Payable InterestExpenseRelatedToAmortizationOfDebtIssuanceRelatedToRelatedPartyNotesPayable	18000	USD
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2020	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2019	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	59000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-452000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2319000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	243000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	116000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	212000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	52000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-310000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-888000	USD
CY2021	nby	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-25000	USD
CY2020	nby	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-816000	USD
CY2019	nby	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-861000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-0	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-9000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-163000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-321000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1841000	USD
CY2021	nby	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-57000	USD
CY2020	nby	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-878000	USD
CY2019	nby	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1066000	USD
CY2021	nby	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	0	USD
CY2020	nby	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	0	USD
CY2019	nby	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	0	USD
CY2021	us-gaap	Increase Decrease In Notes Payable Related Parties Current IncreaseDecreaseInNotesPayableRelatedPartiesCurrent	0	USD
CY2020	us-gaap	Increase Decrease In Notes Payable Related Parties Current IncreaseDecreaseInNotesPayableRelatedPartiesCurrent	73000	USD
CY2019	us-gaap	Increase Decrease In Notes Payable Related Parties Current IncreaseDecreaseInNotesPayableRelatedPartiesCurrent	204000	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12045000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-26000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19000	USD
CY2021	nby	Proceeds From Preferred Stock Issuances Net ProceedsFromPreferredStockIssuancesNet	14908000	USD
CY2020	nby	Proceeds From Preferred Stock Issuances Net ProceedsFromPreferredStockIssuancesNet	0	USD
CY2019	nby	Proceeds From Preferred Stock Issuances Net ProceedsFromPreferredStockIssuancesNet	2598000	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1776000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5220000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6698000	USD
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	7098000	USD
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	67000	USD
CY2021	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
CY2020	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
CY2019	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	1000000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	42000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9192000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4721000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7929000	USD
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	11993000	USD
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-0	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-0	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	52000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	26000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	189000	USD
CY2021	nby	Proceeds From Sale Of Stock Options And Restricted Stock Sold To Cover Taxes ProceedsFromSaleOfStockOptionsAndRestrictedStockSoldToCoverTaxes	0	USD
CY2020	nby	Proceeds From Sale Of Stock Options And Restricted Stock Sold To Cover Taxes ProceedsFromSaleOfStockOptionsAndRestrictedStockSoldToCoverTaxes	0	USD
CY2019	nby	Proceeds From Sale Of Stock Options And Restricted Stock Sold To Cover Taxes ProceedsFromSaleOfStockOptionsAndRestrictedStockSoldToCoverTaxes	4000	USD
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2000000	USD
CY2021	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	105000	USD
CY2020	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
CY2019	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	-0	USD
CY2020	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1563000	USD
CY2019	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	652000	USD
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	-0	USD
CY2020	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1000000	USD
CY2019	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	-0	USD
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	-0	USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	-0	USD
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	202000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16789000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9762000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11702000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4448000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5015000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3754000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12427000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7412000	USD
CY2019	nby	Reclass Of Sublease Security Deposit From Long Term To Short Term ReclassOfSubleaseSecurityDepositFromLongTermToShortTerm	198000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3658000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7979000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12427000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7412000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	49000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	148000	USD
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	21000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	14000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	14000	USD
CY2021	nby	Related Party Loan Interest Paid Via Accounts Receivable RelatedPartyLoanInterestPaidViaAccountsReceivable	0	USD
CY2020	nby	Related Party Loan Interest Paid Via Accounts Receivable RelatedPartyLoanInterestPaidViaAccountsReceivable	277000	USD
CY2019	nby	Related Party Loan Interest Paid Via Accounts Receivable RelatedPartyLoanInterestPaidViaAccountsReceivable	0	USD
CY2021	nby	Addition Of Operating Lease Rightofuse Asset AdditionOfOperatingLeaseRightofuseAsset	376000	USD
CY2020	nby	Addition Of Operating Lease Rightofuse Asset AdditionOfOperatingLeaseRightofuseAsset	0	USD
CY2019	nby	Addition Of Operating Lease Rightofuse Asset AdditionOfOperatingLeaseRightofuseAsset	2473000	USD
CY2021	nby	Change In Accounts Payable And Accrued Liabilities For Property And Equipment Purchases ChangeInAccountsPayableAndAccruedLiabilitiesForPropertyAndEquipmentPurchases	0	USD
CY2020	nby	Change In Accounts Payable And Accrued Liabilities For Property And Equipment Purchases ChangeInAccountsPayableAndAccruedLiabilitiesForPropertyAndEquipmentPurchases	0	USD
CY2019	nby	Change In Accounts Payable And Accrued Liabilities For Property And Equipment Purchases ChangeInAccountsPayableAndAccruedLiabilitiesForPropertyAndEquipmentPurchases	10000	USD
CY2021	nby	Fair Value Of Warrants Issued In Connection With Financings FairValueOfWarrantsIssuedInConnectionWithFinancings	14172000	USD
CY2020	nby	Fair Value Of Warrants Issued In Connection With Financings FairValueOfWarrantsIssuedInConnectionWithFinancings	0	USD
CY2019	nby	Fair Value Of Warrants Issued In Connection With Financings FairValueOfWarrantsIssuedInConnectionWithFinancings	5269000	USD
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	55000	USD
CY2020	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2019	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	584000	USD
CY2021	nby	Reclass O Lease Security From Long Term To Short Term ReclassOLeaseSecurityFromLongTermToShortTerm	0	USD
CY2020	nby	Reclass O Lease Security From Long Term To Short Term ReclassOLeaseSecurityFromLongTermToShortTerm	0	USD
CY2019	nby	Reclass O Lease Security From Long Term To Short Term ReclassOLeaseSecurityFromLongTermToShortTerm	65000	USD
CY2021	nby	Reclass Of Sublease Security Deposit From Long Term To Short Term ReclassOfSubleaseSecurityDepositFromLongTermToShortTerm	0	USD
CY2020	nby	Reclass Of Sublease Security Deposit From Long Term To Short Term ReclassOfSubleaseSecurityDepositFromLongTermToShortTerm	0	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Use of Estimates </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include contract liabilities related to product sales, useful lives for property and equipment and related depreciation calculations, assumptions for valuing options and warrants, the fair value of contingent consideration, intangible assets, and goodwill, stock-based compensation, income taxes and other contingencies</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">These estimates are based on management’s best estimates and judgment. Actual results <em style="font: inherit;"> may </em>differ from these estimates. Estimates, judgments, and assumptions are continuously evaluated and are based on management’s experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Uncertainty about these assumptions, judgments and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7504000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11952000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	475000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	475000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7979000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12427000	USD
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Concentrations of Credit Risk and Major Partners</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits of cash, cash equivalents and restricted cash with a highly-rated, major financial institution in the United States. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Deposits in this bank <em style="font: inherit;"> may </em>exceed the amount of federal insurance provided on such deposits. The Company does <em style="font: inherit;">not</em> believe it is exposed to significant credit risk due to the financial position of the financial institution in which the deposits are held. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">During the year ended <em style="font: inherit;"> December 31, 2021, </em>revenues were derived primarily from sales of Avenova Spray directly to doctors through the Company’s webstore, directly to consumers through Amazon.com, national retailers and to pharmacies via <em style="font: inherit;">three</em> major distribution partners and specialty pharmacies. During the year ended <em style="font: inherit;"> December 31, 2020, </em>revenues were derived primarily from sales of Avenova Spray directly to <em style="font: inherit;">three</em> major distribution partners, to doctors through the Company's internal sales team, and also generated revenue from the sale of <em style="font: inherit;">KN95</em> Masks in response to the national need for personal protective equipment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">During the years ended <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> revenues from each product were as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2019</b></b></p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 55%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Avenova Spray</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">6,844</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">5,974</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">6,347</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;">DERMAdoctor</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">587</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">KN95 Masks</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">3,124</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">NeutroPhase</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">368</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">524</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">209</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other products</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">598</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">294</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total product revenue, net</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">8,397</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">9,916</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">6,556</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other revenue, net</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">43</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total sales, net</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,421</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,934</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,599</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">During the years ended <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> Avenova Spray revenues from our major distribution partners greater than <em style="font: inherit;">10%</em> were as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" rowspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Major distribution</b></p> </td><td> </td><td colspan="2" style="text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"><b><b>2021</b></b></td><td style="padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2019</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Avenova Direct via Amazon</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">59</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">50</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Avenova distributor A</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"></em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"></em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Avenova distributor B</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"></em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"></em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Avenova distributor C</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"></em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"></em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;">Not</em> greater than <em style="font: inherit;">10%</em></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> accounts receivable from our major distribution partners and major retailers greater than <em style="font: inherit;">10%</em> were as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31, </b></b></p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Major distribution partner</b></p> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Major U.S. Retailer</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">33</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"></em></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Avenova Spray Pharmacy Distributor A</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">13</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">18</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Avenova Spray Pharmacy Distributor C</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">11</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">14</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Chongqing Pioneer Pharma Holdings Limited</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"></em></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">16</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Avenova Spray Pharmacy Distributor B</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"></em></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">14</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;">Amazon</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"></em></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">11</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;">Not</em> greater than <em style="font: inherit;">10%</em></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company relies on <em style="font: inherit;">seven</em> contract manufacturers to produce its products. The Company does <em style="font: inherit;">not</em> own any manufacturing facilities and intends to continue to rely on <em style="font: inherit;">third</em> parties for the supply of finished goods. Contract manufacturers <em style="font: inherit;"> may </em>or <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be able to meet the Company’s needs with respect to timing, quantity or quality. In particular, it is possible that we <em style="font: inherit;"> may </em>suffer from unexpected supply chain delays in light of the worldwide COVID-<em style="font: inherit;">19</em> pandemic.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8421000	USD
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9934000	USD
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6599000	USD
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35076000
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21641000
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-150
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-310
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-480
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	641000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	236000	USD
CY2020	nby	Payment For Product Supply Period PaymentForProductSupplyPeriod	P30D
CY2021	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2021Q4	nby	Intangible Assets Including Goodwill Fair Value Disclosure IntangibleAssetsIncludingGoodwillFairValueDisclosure	9788000	USD
CY2021	us-gaap	Advertising Expense AdvertisingExpense	3200000	USD
CY2020	us-gaap	Advertising Expense AdvertisingExpense	1700000	USD
CY2019	us-gaap	Advertising Expense AdvertisingExpense	500000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-5824000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-11039000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-9658000	USD
CY2021	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	735000	USD
CY2020	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	0	USD
CY2019	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	800000	USD
CY2021	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	0	USD
CY2020	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	0	USD
CY2019	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	29000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6559000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-11039000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-10487000	USD
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43657000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11531000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10232000
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10771000
CY2021Q4	nby	Intangible Assets Including Goodwill Fair Value Disclosure IntangibleAssetsIncludingGoodwillFairValueDisclosure	9788000	USD
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	pure
CY2020Q4	nby	Prepaid Inventory PrepaidInventory	0	USD
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	138000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	165000	USD
CY2021Q4	nby	Prepaid Consulting Services PrepaidConsultingServices	68000	USD
CY2020Q4	nby	Prepaid Consulting Services PrepaidConsultingServices	0	USD
CY2021Q4	nby	Prepaid Sales Rebate PrepaidSalesRebate	19000	USD
CY2020Q4	nby	Prepaid Sales Rebate PrepaidSalesRebate	144000	USD
CY2021Q4	nby	Prepaid Security Deposit For Lease PrepaidSecurityDepositForLease	0	USD
CY2020Q4	nby	Prepaid Security Deposit For Lease PrepaidSecurityDepositForLease	65000	USD
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	USD
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	9558000	USD
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	4092000	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	1000	USD
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	USD
CY2021Q4	nby	Prepaid Inventory PrepaidInventory	368000	USD
CY2021Q4	nby	Prepaid Dues And Subscription PrepaidDuesAndSubscription	18000	USD
CY2020Q4	nby	Prepaid Dues And Subscription PrepaidDuesAndSubscription	53000	USD
CY2021Q4	us-gaap	Prepaid Rent PrepaidRent	14000	USD
CY2020Q4	us-gaap	Prepaid Rent PrepaidRent	0	USD
CY2021Q4	nby	Prepaid Patents PrepaidPatents	9000	USD
CY2020Q4	nby	Prepaid Patents PrepaidPatents	47000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	144000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	102000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	778000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	576000	USD
CY2021Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1179000	USD
CY2020Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	159000	USD
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2682000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	685000	USD
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	641000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	236000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	3220000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	608000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	834000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	686000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	641000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	602000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	193000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	84000	USD
CY2021	us-gaap	Depreciation Depreciation	59000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	51000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	65000	USD
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	12000	USD
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	10000	USD
CY2021	us-gaap	Lease Cost LeaseCost	418000	USD
CY2020	us-gaap	Lease Cost LeaseCost	405000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	475000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	826000	USD
CY2021	us-gaap	Sublease Income SubleaseIncome	-0	USD
CY2020	us-gaap	Sublease Income SubleaseIncome	421000	USD
CY2021Q4	nby	Contract With Customer Accrued Liabilities Current ContractWithCustomerAccruedLiabilitiesCurrent	1289000	USD
CY2020Q4	nby	Contract With Customer Accrued Liabilities Current ContractWithCustomerAccruedLiabilitiesCurrent	730000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	443000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	632000	USD
CY2021Q4	nby	Accrued Sublease Security Deposit Current AccruedSubleaseSecurityDepositCurrent	0	USD
CY2020Q4	nby	Accrued Sublease Security Deposit Current AccruedSubleaseSecurityDepositCurrent	198000	USD
CY2021Q4	nby	Accrued Inventory Current AccruedInventoryCurrent	0	USD
CY2020Q4	nby	Accrued Inventory Current AccruedInventoryCurrent	181000	USD
CY2021Q4	nby	Accrued Consulting Service Current AccruedConsultingServiceCurrent	0	USD
CY2020Q4	nby	Accrued Consulting Service Current AccruedConsultingServiceCurrent	98000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	360000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	276000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2092000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2115000	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	418000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	927000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y6M
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y2M12D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06	pure
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	216000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	129000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	130000	USD
CY2021Q4	nby	Lessee Operating Lease Liability Payments Due After Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree	0	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	475000	USD
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	7082000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	14000
CY2020Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6800000	USD
CY2021	nby	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	15000
CY2021	nby	Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice	0.67
CY2021	nby	Class Of Warrant Or Right Forfeited During Period ClassOfWarrantOrRightForfeitedDuringPeriod	-0
CY2021	nby	Class Of Warrant Or Right Forfeited During Period Weighted Average Exercise Price ClassOfWarrantOrRightForfeitedDuringPeriodWeightedAverageExercisePrice	0
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	29000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	446000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	200000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	246000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	446000	USD
CY2021Q4	us-gaap	Warrants And Rights Outstanding Measurement Input WarrantsAndRightsOutstandingMeasurementInput	0.38	pure
CY2021Q4	us-gaap	Warrants And Rights Outstanding Measurement Input WarrantsAndRightsOutstandingMeasurementInput	0.25	pure
CY2020Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	200000	USD
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	7067000
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.63
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.63
CY2020Q4	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding	3165000
CY2020Q4	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice	2.05
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	189000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	516000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.66
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1528000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	272000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	2.35
CY2021Q4	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding	4449000
CY2021Q4	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice	1.39
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	460000	USD
CY2021Q4	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingNumber	4125000
CY2021Q4	nby	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.46
CY2021	nby	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm	P7Y6M
CY2021Q4	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	406000	USD
CY2021Q4	nby	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedInPeriod	2150000
CY2021Q4	nby	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedInPeriodWeightedAverageGrantDateFairValue	2.42
CY2021	nby	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedWeightedAverageRemainingContractualTerm	P5Y4M24D
CY2021Q4	nby	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAggregateIntrinsicValue	8000	USD
CY2021Q4	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Number ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableNumber	2150000
CY2021Q4	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageExercisePrice	2.42
CY2021	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageRemainingContractualTerm	P5Y10M24D
CY2021Q4	nby	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Aggregate Intrinsic Value SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableAggregateIntrinsicValue	8000	USD
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	20000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	83000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	200000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1200000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M14D
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	933000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	532000	USD
CY2020	nby	Contract With Customer Liability Current Additions ContractWithCustomerLiabilityCurrentAdditions	2340000	USD
CY2020	nby	Contract With Customer Liability Current Deductions ContractWithCustomerLiabilityCurrentDeductions	2199000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	575000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	486000	USD
CY2020Q4	nby	Contract With Customer Liability Deferred Revenue Current ContractWithCustomerLiabilityDeferredRevenueCurrent	2000	USD
CY2021	nby	Contract With Customer Liability Deferred Revenue Current Additions ContractWithCustomerLiabilityDeferredRevenueCurrentAdditions	176000	USD
CY2021	nby	Contract With Customer Liability Deferred Revenue Current Deductions ContractWithCustomerLiabilityDeferredRevenueCurrentDeductions	124000	USD
CY2021Q4	nby	Contract With Customer Liability Deferred Revenue Current ContractWithCustomerLiabilityDeferredRevenueCurrent	54000	USD
CY2020Q4	nby	Contract With Customer Liability Product Contracts Current ContractWithCustomerLiabilityProductContractsCurrent	573000	USD
CY2021	nby	Contract With Customer Liability Product Distribution Current Additions ContractWithCustomerLiabilityProductDistributionCurrentAdditions	1851000	USD
CY2021	nby	Contract With Customer Liability Product Distribution Current Deductions ContractWithCustomerLiabilityProductDistributionCurrentDeductions	1154000	USD
CY2021Q4	nby	Contract With Customer Liability Product Contracts Current ContractWithCustomerLiabilityProductContractsCurrent	1270000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	575000	USD
CY2021	nby	Contract With Customer Liability Current Additions ContractWithCustomerLiabilityCurrentAdditions	2027000	USD
CY2021	nby	Contract With Customer Liability Current Deductions ContractWithCustomerLiabilityCurrentDeductions	1278000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1324000	USD
CY2019Q4	nby	Contract With Customer Liability Deferred Revenue Current ContractWithCustomerLiabilityDeferredRevenueCurrent	0	USD
CY2020	nby	Contract With Customer Liability Deferred Revenue Current Additions ContractWithCustomerLiabilityDeferredRevenueCurrentAdditions	2000	USD
CY2020	nby	Contract With Customer Liability Deferred Revenue Current Deductions ContractWithCustomerLiabilityDeferredRevenueCurrentDeductions	-0	USD
CY2020Q4	nby	Contract With Customer Liability Deferred Revenue Current ContractWithCustomerLiabilityDeferredRevenueCurrent	2000	USD
CY2019Q4	nby	Contract With Customer Liability Product Contracts Current ContractWithCustomerLiabilityProductContractsCurrent	434000	USD
CY2020	nby	Contract With Customer Liability Product Distribution Current Additions ContractWithCustomerLiabilityProductDistributionCurrentAdditions	2338000	USD
CY2020	nby	Contract With Customer Liability Product Distribution Current Deductions ContractWithCustomerLiabilityProductDistributionCurrentDeductions	2199000	USD
CY2020Q4	nby	Contract With Customer Liability Product Contracts Current ContractWithCustomerLiabilityProductContractsCurrent	573000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	434000	USD
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8421000	USD
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9934000	USD
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6599000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	5000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	6000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-5824000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-11034000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-9652000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5824000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11034000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9652000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	6000	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	641000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	641000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	306000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	267000	USD
CY2021Q4	nby	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	19000	USD
CY2020Q4	nby	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	109000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	10000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	2000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	376000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	81000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	35691000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	33005000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2800000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1300000	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2200000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	33455000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	31115000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	884000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	790000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	19000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	108000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	19000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	108000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35672000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	32897000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	974000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	974000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	0	USD
CY2020Q4	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	200000	USD
CY2021Q4	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	0	USD
CY2020Q4	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	8000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	974000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	974000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.112	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.032	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.031	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.477	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.117	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.230	pure
CY2021	nby	Effective Income Tax Rate Reconciliation Warrant And Equity Expenses Percent EffectiveIncomeTaxRateReconciliationWarrantAndEquityExpensesPercent	0.167	pure
CY2020	nby	Effective Income Tax Rate Reconciliation Warrant And Equity Expenses Percent EffectiveIncomeTaxRateReconciliationWarrantAndEquityExpensesPercent	-0.103	pure
CY2019	nby	Effective Income Tax Rate Reconciliation Warrant And Equity Expenses Percent EffectiveIncomeTaxRateReconciliationWarrantAndEquityExpensesPercent	0.017	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.011	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.040	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.037	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.017	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.003	pure
CY2021	nby	Effective Income Tax Rate Reconciliation Impact Of162m Percent EffectiveIncomeTaxRateReconciliationImpactOf162mPercent	0	pure
CY2020	nby	Effective Income Tax Rate Reconciliation Impact Of162m Percent EffectiveIncomeTaxRateReconciliationImpactOf162mPercent	0	pure
CY2019	nby	Effective Income Tax Rate Reconciliation Impact Of162m Percent EffectiveIncomeTaxRateReconciliationImpactOf162mPercent	0.011	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001	pure
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001	pure
CY2021	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	368000	USD
CY2020	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	524000	USD
CY2019	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	250000	USD
CY2021	us-gaap	Related Party Costs RelatedPartyCosts	325000	USD
CY2020	us-gaap	Related Party Costs RelatedPartyCosts	384000	USD
CY2019	us-gaap	Related Party Costs RelatedPartyCosts	176000	USD
CY2021Q4	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	100000	USD
CY2021	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	0	USD
CY2020	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	251000	USD
CY2019	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	409000	USD
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	pure
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8421000	USD
CY2021	nby	Percentage Of Revenue PercentageOfRevenue	1	pure
CY2021	us-gaap	Gross Profit GrossProfit	5645000	USD
CY2021	nby	Percentage Of Gross Margin PercentageOfGrossMargin	1	pure
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000

Files In Submission

Name	View Source	Status
0001437749-22-007543-index-headers.html	Edgar Link	pending
0001437749-22-007543-index.html	Edgar Link	pending
0001437749-22-007543.txt	Edgar Link	pending
0001437749-22-007543-xbrl.zip	Edgar Link	pending
ex_343782.htm	Edgar Link	pending
ex_343783.htm	Edgar Link	pending
ex_343784.htm	Edgar Link	pending
ex_343785.htm	Edgar Link	pending
ex_343786.htm	Edgar Link	pending
ex_343787.htm	Edgar Link	pending
ex_346224.htm	Edgar Link	pending
ex_346225.htm	Edgar Link	pending
ex_348186.htm	Edgar Link	pending
ex_350338.htm	Edgar Link	pending
ex_351428.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
logo01.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nby-20211231.xsd	Edgar Link	pending
nby-20211231_cal.xml	Edgar Link	unprocessable
nby-20211231_def.xml	Edgar Link	unprocessable
nby-20211231_lab.xml	Edgar Link	unprocessable
nby-20211231_pre.xml	Edgar Link	unprocessable
nby20211231b_10k.htm	Edgar Link	pending
nby20211231b_10k_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NBY
NovaBay Pharmaceuticals Inc Stock $nby

2021 Q4 Form 10-K Financial Statement

#000143774922007543 Filed on March 29, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NBY NovaBay Pharmaceuticals Inc Stock $nby

2021 Q4 Form 10-K Financial Statement

#000143774922007543 Filed on March 29, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NBY
NovaBay Pharmaceuticals Inc Stock $nby